Harvey Gap Surgery for the Treatment of Allergic Rhinitis Proves Long-Term Effectiveness and Safety
Nov 29, 2024
A study found that Harvey Gap surgery performed on allergic rhinitis patients remains effective more than a year after surgery and has no significant complications. In particular, symptoms such as nasal congestion and runny nose, which are major symptoms of rhinitis, remained improved more than three years after surgery.
A joint research team led by Professor Park Sang-cheol of the Department of Otolaryngology at Hallym University Gangnam Sacred Heart Hospital, Professor Kim Dong-gyu of the Department of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital, and Professor Kim Hyun-jung of Korea University's Institute of Evidence-Centered Medicine published this result in a paper titled 「Long-term effects of Harvey Gap surgery in allergic rhinitis patients: Systematic Review and Meta-analysis」.
If a patient with allergic rhinitis does not respond to drug treatment, surgical treatment is performed. Harvey Gap surgery is a surgical method to reduce Harvey Gap hypertrophy, the main cause of nasal congestion, and is considered an effective rhinitis treatment. However, there has not been much research on the long-term consequences of Harvey's laparotomy.
In response, Professor Park Sang-chul's joint research team conducted a systematic literature review and meta-analysis on Harvey Gap surgery for the first time in Korea with the support of the Korean Society of Asthma Allergy. The research team analyzed the data of 1411 patients used in 18 papers.
As a result of the analysis, subjective symptoms such as nasal congestion, runny nose, sneezing, and itching after Harvey Gap surgery, as well as objective indicators such as total nasal volume and nasal resistance, were significantly improved. In addition, the effect was found to have been maintained for more than 1 year after surgery. In particular, it was confirmed that some follow-up data remained improved for more than three years.
Compared to before surgery, the weighted mean difference (WMD) of the symptom score after one year of surgery was significantly reduced to 4.60 for nasal congestion, 3.12 for runny nose, 2.64 for sneezing, and 0.16 for nasal resistance. On the other hand, the total nasal volume (WMD 0.96) was significantly increased and rhinitis was improved. Even after more than three years of follow-up, it was confirmed that symptoms of nasal congestion (WMD 5.18), runny nose (WMD 3.57), and sneezing (WMD 2.95) were improved, and there were no significant complications.
In recognition of its excellence, the study won the Best Presentation Award at the 73rd Annual Meeting of Japan's Society of Allergy held in Kyoto, Japan, from Oct. 18 to 20.
Professor Park Sang-chul said, "The research has enabled us to provide an important objective basis for determining treatment methods for patients with allergic rhinitis. It is all the more meaningful in recognition of the excellence of Korean research in an international session attended by outstanding researchers from Korea, China, and Japan, and we will continue to focus on research to improve the prognosis of patients with allergic rhinitis."
Meanwhile, Professor Park Sang-chul is actively conducting basic-clinical brokerage research to develop new treatments through immunological research on respiratory allergic diseases, such as establishing a biobank at the Intermediary Medical Research Institute of Gangnam Sacred Heart Hospital at Hallym University. At the 2024 Korean Astronomical Allergy Association Fall Conference held on November 9, it won the Academic Research Fund in recognition of the excellence of the research plan 'Intrinsic Type and Cluster Analysis of Patients with Allergic Rhinitis and Chronic Sinusitis'.
A joint research team led by Professor Park Sang-cheol of the Department of Otolaryngology at Hallym University Gangnam Sacred Heart Hospital, Professor Kim Dong-gyu of the Department of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital, and Professor Kim Hyun-jung of Korea University's Institute of Evidence-Centered Medicine published this result in a paper titled 「Long-term effects of Harvey Gap surgery in allergic rhinitis patients: Systematic Review and Meta-analysis」.
If a patient with allergic rhinitis does not respond to drug treatment, surgical treatment is performed. Harvey Gap surgery is a surgical method to reduce Harvey Gap hypertrophy, the main cause of nasal congestion, and is considered an effective rhinitis treatment. However, there has not been much research on the long-term consequences of Harvey's laparotomy.
In response, Professor Park Sang-chul's joint research team conducted a systematic literature review and meta-analysis on Harvey Gap surgery for the first time in Korea with the support of the Korean Society of Asthma Allergy. The research team analyzed the data of 1411 patients used in 18 papers.
As a result of the analysis, subjective symptoms such as nasal congestion, runny nose, sneezing, and itching after Harvey Gap surgery, as well as objective indicators such as total nasal volume and nasal resistance, were significantly improved. In addition, the effect was found to have been maintained for more than 1 year after surgery. In particular, it was confirmed that some follow-up data remained improved for more than three years.
Compared to before surgery, the weighted mean difference (WMD) of the symptom score after one year of surgery was significantly reduced to 4.60 for nasal congestion, 3.12 for runny nose, 2.64 for sneezing, and 0.16 for nasal resistance. On the other hand, the total nasal volume (WMD 0.96) was significantly increased and rhinitis was improved. Even after more than three years of follow-up, it was confirmed that symptoms of nasal congestion (WMD 5.18), runny nose (WMD 3.57), and sneezing (WMD 2.95) were improved, and there were no significant complications.
In recognition of its excellence, the study won the Best Presentation Award at the 73rd Annual Meeting of Japan's Society of Allergy held in Kyoto, Japan, from Oct. 18 to 20.
Professor Park Sang-chul said, "The research has enabled us to provide an important objective basis for determining treatment methods for patients with allergic rhinitis. It is all the more meaningful in recognition of the excellence of Korean research in an international session attended by outstanding researchers from Korea, China, and Japan, and we will continue to focus on research to improve the prognosis of patients with allergic rhinitis."
Meanwhile, Professor Park Sang-chul is actively conducting basic-clinical brokerage research to develop new treatments through immunological research on respiratory allergic diseases, such as establishing a biobank at the Intermediary Medical Research Institute of Gangnam Sacred Heart Hospital at Hallym University. At the 2024 Korean Astronomical Allergy Association Fall Conference held on November 9, it won the Academic Research Fund in recognition of the excellence of the research plan 'Intrinsic Type and Cluster Analysis of Patients with Allergic Rhinitis and Chronic Sinusitis'.
|
bellho@sportschosun.com
